Fig. 2From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaMean (95% CI) change from baseline in absolute CST values in the study eye (FAS). CI, confidence interval; CST, central subfield thickness; FAS, full analysis set; LDD, last dose date; LOCF, last observation carried forwardBack to article page